Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

Worldwide Antiretroviral Drug Sales 2006*

September 2007

DrugCompany$ MillionChange From 2005Notes
TruvadaGilead1,194+210%
KaletraAbbott1,135+13%
CombivirGlaxoSmithKline977-8%
ReyatazBristol-Myers Squibb931+34%
SustivaBristol-Myers Squibb791+16%Includes $76 million related to Atripla sales
VireadGilead689-12%
TrizivirGlaxoSmithKline496-10%
EpzicomGlaxoSmithKline446+207%
EpivirGlaxoSmithKline374-11%
ViramuneBoehringer-Ingelheim353-4%Estimate, based on 276 Euros
CrixivanMerck327-6%
FuzeonRoche250+19%Estimate, based on 312 Swiss Francs
Lexiva/AgeneraseGlaxoSmithKline242+19%
ZiagenGlaxoSmithKline216-13%
AtriplaGilead206-Gilead recorded 100% of Atripla sales, then paid BMS $76 million for the efavirenz
ZeritBristol-Myers Squibb155-18%
Invirase/FortovaseRoche145+28%Estimate, based on 182 Swiss Francs
AptivusBoehringer-Ingelheim67-Estimate, based on 53 Euros
EmtrivaGilead36-13%
TOTAL
9,030+14%
* Does not include unreported drugs (Videx, Norvir, Viracept, Rescriptor, Retrovir)

Source: AIDSMeds.com based on SEC filings.




  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by Treatment Action Group. It is a part of the publication TAGline.
 

Tools
 

Advertisement